GPR171 Lentiviral Activation Particles (h): sc-412047-LAC

GPR171 encodes an orphan class A (rhodopsin-like) G protein-coupled receptor that participates in neuromodulatory signaling and regulation of intracellular second-messenger pathways, including GPCR-mediated cAMP and MAPK cascades. In the central nervous system, GPR171 has been linked to control of feeding behavior, reward circuitry, and stress-associated responses, consistent with roles in synaptic communication and neuronal network excitability. Transcriptomic and functional studies have associated altered GPR171 activity with neuropsychiatric and metabolic phenotypes, supporting its utility as a mechanistic node for dissecting circuit-level signaling. As a membrane receptor, it provides a tractable model for studying receptor trafficking, ligand discovery, and downstream effector coupling in human cell systems.

GPR171 Lentiviral Activation Particles (h) address this need by packaging the complete synergistic activation mediator (SAM) transcriptional activation system into transduction-ready, high-titer lentiviral particles, enabling efficient GPR171 upregulation across a broader range of human cell types.

GPR171 Lentiviral Activation Particles (h) deliver all functional components of the synergistic activation mediator (SAM) system via lentiviral transduction. The system comprises three particle preparations co-transduced into target cells: one encoding catalytically inactive dCas9 (D10A and N863A mutations) fused to the VP64 transactivation domain with a blasticidin resistance gene; one encoding the MS2-p65-HSF1 fusion protein with a hygromycin resistance gene; and one encoding a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers with a puromycin resistance gene. Following lentiviral transduction and genomic integration of the expression cassettes, the SAM components are stably expressed and assemble at the target locus within the proximal promoter region upstream of the GPR171 transcriptional start site, where VP64, p65, and HSF1 act cooperatively to recruit endogenous transcriptional machinery and drive sustained upregulation of endogenous GPR171 expression. The use of nuclease-inactive dCas9 avoids the introduction of double-strand DNA breaks and preserves the native GPR171 genomic locus and regulatory architecture.

The lentiviral format offers several practical advantages: stable genomic integration supports heritable activation across cell divisions; high-titer particle preparations eliminate the need for in-house viral production; and compatibility with primary, non-dividing, and transfection-resistant cell types expands experimental accessibility. Successful transduction can be confirmed and enriched through triple antibiotic selection using puromycin, hygromycin, and blasticidin.

For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.